Non Small Cell Lung Cancer — Expanded Access Programs

• Study on MK-1084 and Other Treatments for Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
• Study on Pembrolizumab and Berahyaluronidase Alfa for Treating Newly Diagnosed Metastatic Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
• Study on Intismeran (V940) With or Without Pembrolizumab for High-Risk Stage I Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
• Study on Calderasib and Durvalumab for Treating Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
• Study on Investigational Combination Therapy with BNT326 and BNT327 for Advanced Non-Small Cell Lung Cancer (NSCLC) — BioNTech SE
• First-in-Human Study of CKD-703 for Advanced Solid Tumors and Non-Small Cell Lung Cancer — Chong Kun Dang Pharmaceutical
• First Human Trial of BLU-924 for Advanced Cancers with KRAS Mutations — Blueprint Medicines Corporation
• Global Study on Rilvegostomig or Pembrolizumab with Chemotherapy for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer — AstraZeneca
• Global Study on Durvalumab and Domvanalimab After Chemoradiation for Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) — AstraZeneca
• Global Study on Durvalumab with Oleclumab or Monalizumab After Chemoradiation for Stage III Unresectable Non-Small Cell Lung Cancer — AstraZeneca
• Global Study on Osimertinib for Patients with Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer After Tumor Removal — AstraZeneca
• Study on the Safety and Effectiveness of ENV-501 for Patients with HER3-Positive Solid Tumors — Endeavor Biomedicines, Inc.
• Study on CLN-081 for Patients with Non-Small Cell Lung Cancer — Cullinan Therapeutics Inc.
• Study on VS-7375 for Patients with KRAS G12D-Mutated Solid Tumors — Verastem, Inc.
• Phase 2 Study on Immunotherapy for Non-Small Cell Lung Cancer Resistant to Previous Treatments — M.D. Anderson Cancer Center
• Phase 2 Study of Adding Vitamin C to Chemotherapy and Radiation for Non-Small Cell Lung Cancer — Joseph J. Cullen, MD, FACS
• Phase 2 Study of Osimertinib and Selumetinib for Advanced EGFR Mutant Lung Cancer — Dana-Farber Cancer Institute
• Phase 2 Study of VS-7375 for Patients with KRAS G12D-Mutated Non-Small Cell Lung Cancer — Verastem, Inc.
• Phase 2 Study of Zanidatamab for Patients with HER2-positive Tumors — Jazz Pharmaceuticals
• Phase II Study of HLX43 for Advanced Non-Small Cell Lung Cancer (NSCLC) — Shanghai Henlius Biotech
• Phase III Study of Dato-DXd and Rilvegostomig for Stage I Adenocarcinoma NSCLC After Tumor Removal — AstraZeneca
• Study Comparing Savolitinib and Osimertinib with Savolitinib and Placebo in Patients with Advanced Lung Cancer — AstraZeneca
• Study on FMC-376 for Patients with KRAS G12C Mutated Advanced Solid Tumors — Frontier Medicines Corporation
• Study on Combining Immunotherapy and Radiotherapy for Non-Small Cell Lung Cancer — University of Chicago
• Study Comparing Divarasib and Pembrolizumab with Standard Chemotherapy for Advanced KRAS G12C-Mutated Lung Cancer — Hoffmann-La Roche
• Study Comparing Divarasib with Sotorasib or Adagrasib for Treating Advanced KRAS G12C-positive Lung Cancer — Hoffmann-La Roche
• Study on the Effectiveness and Safety of Different Treatments for Stage III Non-Small Cell Lung Cancer — Hoffmann-La Roche
• Study on the Safety and Effects of Divarasib with Other Cancer Treatments for Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation — Hoffmann-La Roche
• Study on Abemaciclib for Patients with Previously Treated KRAS Mutated Lung Cancer — Eli Lilly and Company
• Study on BIO 300 and Chest Radiation Therapy for People with Non-Small Cell Lung Cancer and Interstitial Lung Disease — Memorial Sloan Kettering Cancer Center
• Study on BMS-986340 Alone and with Nivolumab or Docetaxel for Advanced Solid Tumors — Bristol-Myers Squibb
• Study on Cemiplimab with Chemotherapy and Other Treatments for Adults with Operable Non-Small Cell Lung Cancer — Regeneron Pharmaceuticals
• A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors — Kahr Medical
• Study Comparing DZD9008 with Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer — Dizal Pharmaceuticals
• Study on GV20-0251 Alone and with Pembrolizumab for Treating Solid Tumor Cancers — GV20 Therapeutics
• Study on IBI363 for Patients with Advanced Solid Tumors — Innovent Biologics (Suzhou) Co. Ltd.
• Study on Ivonescimab with Dato-DXd or Osimertinib for Non-Small Cell Lung Cancer — Memorial Sloan Kettering Cancer Center
• Study on Ivonescimab for Treating Non-Small Cell Lung Cancer — Memorial Sloan Kettering Cancer Center
• Study on Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People with Non-Small Cell Lung Cancer — Memorial Sloan Kettering Cancer Center
• Study on Lorlatinib and Ramucirumab Combination for Lung Cancer — Memorial Sloan Kettering Cancer Center
• Study of MK-1084 and Pembrolizumab for Treating KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer with High PD-L1 Levels — Merck Sharp & Dohme LLC
• Study on Multiple Treatments for Patients with Certain Biomarkers and Resectable Stages IB-III Non-Small Cell Lung Cancer — Genentech, Inc.
• Study on Durvalumab and Chemotherapy Before and After Surgery for Treating Resectable Non-small Cell Lung Cancer — AstraZeneca
• Study on New Treatment Combinations for Non-Small Cell Lung Cancer (NSCLC) — AstraZeneca
• Study on OR502, a Monoclonal Antibody Targeting LILRB2, Alone and with Other Cancer Treatments — OncoResponse, Inc.
• Study on Oral Alintegimod with Ipilimumab and Nivolumab for Cancer Treatment — 7 Hills Pharma, LLC
• Study on Osimertinib With or Without Chemotherapy for First-Line Treatment in Patients with EGFR-Mutated Non-Small Cell Lung Cancer — AstraZeneca
• Study on Osimertinib With or Without Chemotherapy Compared to Chemotherapy Alone for Treating EGFRm Positive Non-Small Cell Lung Cancer Before Surgery — AstraZeneca
• Study on Patient Preference for Subcutaneous vs. Intravenous Pembrolizumab in Various Cancers — Merck Sharp & Dohme LLC
• Study on Pembrolizumab With or Without Chemotherapy and Additional Treatments for Advanced Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
• Study on Selpercatinib (LOXO-292) for Advanced Solid Tumors, RET Fusion-Positive Tumors, and Medullary Thyroid Cancer — Loxo Oncology, Inc.
• Study on Targeted Radiation Therapy for People with Metastatic Non-Small Cell Lung Cancer (NSCLC) — Memorial Sloan Kettering Cancer Center
• Study on Tislelizumab with New Treatments for Non-Small Cell Lung Cancer — BeiGene
• Study on Trastuzumab Deruxtecan for People with Non-Small Cell Lung Cancer — Memorial Sloan Kettering Cancer Center
• Study of V940 Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Patients with Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
• Study Comparing Valemetostat Tosylate and Pembrolizumab with Pembrolizumab Alone for First-Line Treatment of NSCLC Without Specific Genetic Changes — Daiichi Sankyo
• Study on the Safety and Effects of Telisotuzumab Vedotin for Previously Treated Non-Squamous Non-Small Cell Lung Cancer — AbbVie
• Study Comparing IV Telisotuzumab Vedotin and IV Docetaxel in Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer — AbbVie
• Study on Pembrolizumab With or Without Sacituzumab Tirumotecan for Treating Non-Small Cell Lung Cancer After Surgery — Merck Sharp & Dohme LLC
• Study on the Effectiveness of WSD0922-FU in Patients with Advanced Non-Small Cell Lung Cancer with C797S Mutation — Wayshine Biopharm, Inc.
• Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-squamous Non-small Cell Lung Cancer — Bristol-Myers Squibb
• Study Comparing Chemotherapy Plus Osimertinib to Chemotherapy Plus Placebo in Patients with Non-Small Cell Lung Cancer (NSCLC) — AstraZeneca
• Study on the Effectiveness and Safety of Divarasib Compared to Immunotherapy or Observation in Patients with Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer — Hoffmann-La Roche
• Study on the Effectiveness and Safety of Targeted Therapies for Non-Small Cell Lung Cancer (NSCLC) — Hoffmann-La Roche
• A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC — Teligene US
• Study on the Safety and Effectiveness of A2B530 CAR T-Cell Therapy for Solid Tumors with CEA Expression and HLA-A*02 Loss — A2 Biotherapeutics Inc.
• Study on the Safety and Effectiveness of A2B694 CAR T-Cell Therapy for Solid Tumors with MSLN Expression and HLA-A*02 Loss — A2 Biotherapeutics Inc.
• Study on Two Dosing Methods of Nivolumab with Ipilimumab and Chemotherapy for Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer — Bristol-Myers Squibb
• Study on ANS02 for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer — Avistone Biotechnology Co., Ltd.
• Study on the Safety of AZD6750 for Adults with Advanced or Metastatic Solid Tumors — AstraZeneca
• Study on PF-08634404 with Chemotherapy for Adults with Advanced or Metastatic Non-Small Cell Lung Cancer — Pfizer
• Study on How Fianlimab with Cemiplimab and Chemotherapy Works Compared to Cemiplimab and Chemotherapy for Treating Advanced Non-Small Cell Lung Cancer — Regeneron Pharmaceuticals
• Study on Adagrasib and SRS for Patients with KRAS G12C-Mutated Lung Cancer with Untreated Brain Metastases — Ryan Gentzler, MD
• Study on Using Genetically Modified T-Cells to Target Cancer Mutations in People with Metastatic Cancer — National Cancer Institute (NCI)
• Study on Amivantamab with Tyrosine Kinase Inhibitors for Advanced Non-Small Cell Lung Cancer with ALK, ROS1, or RET Alterations — University of Colorado, Denver
• Expanded Access Program for Zipalertinib in Advanced Non-Small Cell Lung Cancer — Taiho Oncology, Inc.
• Study on Oral EGFR Inhibitor Sunvozertinib for Advanced Non-Small Cell Lung Cancer with EGFR or HER2 Mutation — Dizal Pharmaceuticals
• Study on Entrectinib for Treating Solid Tumors with Specific Gene Changes — Hoffmann-La Roche
• Study on Zongertinib for Treating Surgically Removed Non-Small Cell Lung Cancer with HER2 Mutations — Boehringer Ingelheim
• Study on Low-Dose Radiation, Ipilimumab, and Nivolumab Before Surgery for Non-Small Cell Lung Cancer — Brown University
• Study on Cabozantinib for Patients with Specific Gene Changes in Advanced Non-Small Cell Lung Cancer — Memorial Sloan Kettering Cancer Center
• Study on CAN-2409 Plus Prodrug with Standard Immune Therapy for Advanced Lung Cancer — Candel Therapeutics, Inc.
• Study on Carboplatin, Paclitaxel, and Ramucirumab for Non-Small Cell Lung Cancer After Pemetrexed or Pembrolizumab Maintenance — Abramson Cancer Center at Penn Medicine
• Study on Ivonescimab for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer — Summit Therapeutics
• Study on Ivonescimab for Initial Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Levels — Summit Therapeutics
• Study on Using a Blood Test to Predict Treatment Response and Detect Remaining Cancer in Non-Small Cell Lung Cancer — University of Miami
• Study for Continued Access to Dabrafenib and/or Trametinib Treatment — Novartis Pharmaceuticals
• Study on Whether Durvalumab and Radiation Therapy Can Slow Down Non-Small Cell Lung Cancer — Memorial Sloan Kettering Cancer Center
• DISCERN: Comparing Two Immune Therapy Combinations for PD-L1 Negative Non-Small Cell Lung Cancer — University of Alabama at Birmingham
• Study on Reduced Dose Chemotherapy for Lung Cancer Patients with Other Health Conditions — Fox Chase Cancer Center
• Study on MDX2001 for Patients with Advanced Solid Tumors — ModeX Therapeutics, An OPKO Health Company
• Study on Mavrostobart (PT199) Alone and with Other Cancer Treatments (MORNINGSTAR Study) — Phanes Therapeutics
• Study on Lower Dose 3-Session Radiation Therapy for Lung Cancer Near the Center of the Chest — Yale University
• Study on DRP-104 for Patients with Specific Genetic Changes in Non-Small Cell Lung Cancer — NYU Langone Health
• Early Access Program for HER2/HER3 Bispecific Antibody MCLA-128 for Patients with Advanced NRG1-Fusion Positive Solid Tumors — Merus N.V.
• Study on How the Timing of Immunotherapy Infusions Affects Treatment in Solid Tumors — UNC Lineberger Comprehensive Cancer Center
• Study on the Effectiveness and Safety of Olvimulogene Nanivacirepvec with Chemotherapy and Immune Therapy Compared to Docetaxel in Non-Small Cell Lung Cancer (NSCLC) — Genelux Corporation
• Study on Pembrolizumab with Chemotherapy Before and After Surgery for Treatable Stage II, IIIA, and IIIB Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
• Study on AL3818 and Nivolumab for Treating Advanced Solid Tumors — Sarcoma Oncology Research Center, LLC
• Study Comparing Ensartinib to Crizotinib in ALK Positive Non-Small Cell Lung Cancer Patients — Xcovery Holdings, Inc.
• Expanded Access for Treating Cancers with RET Activation — Eli Lilly and Company
• Access Program for Neladalkib (NVL-655) for Patients with Advanced ALK+ Lung Cancer — Nuvalent Inc.
• Access to ABBV-400 Before Official Approval — AbbVie
• Expanded Access to Ensartinib for Patients with ALK+ Non-Small Cell Lung Cancer — Xcovery Holdings, Inc.
• Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies — xCures
• Study on EZH2 Inhibitor Tulmimetostat and PD-1 Blockade for Advanced Non-Small Cell Lung Cancer — VA Office of Research and Development
• Study on the Safety and Effectiveness of TUB-040 for Ovarian and Non-Small Cell Lung Cancer — Tubulis GmbH
• First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations — Scorpion Therapeutics, Inc.
• Study on FOG-001 for Advanced or Metastatic Solid Tumors — Fog Pharmaceuticals, Inc.
• Study on GI-101 Alone or with Pembrolizumab, Lenvatinib, or Local Radiotherapy for Advanced Solid Tumors — GI Innovation, Inc.
• Study on Using Stereotactic Body Radiotherapy (SBRT) with Standard Treatment for Cancer That Has Spread — Memorial Sloan Kettering Cancer Center
• Study on IPH5201 and Durvalumab for Patients with Resectable Non-Small Cell Lung Cancer (MATISSE) — Innate Pharma
• JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer — University of Texas Southwestern Medical Center
• Lorlatinib Continuation Study — Pfizer
• Study on MPDL3280A with Chemotherapy and Radiation for Lung Cancer — M.D. Anderson Cancer Center
• Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer — Dana-Farber Cancer Institute
• Study on Neladalkib (NVL-655) for Patients with Untreated Advanced ALK-Positive Non-Small Cell Lung Cancer — Nuvalent Inc.
• Study on Pre-Surgery and Post-Surgery Treatment for Resectable Non-Small Cell Lung Cancer — AstraZeneca
• Study on Cemiplimab Before Surgery for Treating Resectable Lung, Liver, and Head and Neck Cancers in Adults — Regeneron Pharmaceuticals
• Study on Neoadjuvant Dupilumab and Cemiplimab for Early-stage Resectable Non-Small Cell Lung Cancer (NSCLC) — Icahn School of Medicine at Mount Sinai

Looking for a program not shown above? Search the full catalog for “Non Small Cell Lung Cancer” to see every match including additional filters.